^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Cutaneous Melanoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet
    Title:

    Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Published date:
    04/12/2021
    Excerpt:
    In the 853 patients with PD-L1-positive tumours, 3·5-year distant metastasis-free survival was 66·7% (95% CI 61·8–71·2) in the pembrolizumab group and 51·6% (46·6–56·4) in the placebo group (HR 0·61 [95% CI 0·49–0·76]; p<0·0001)....Pembrolizumab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median follow-up, which was consistent with the improvement in recurrence-free survival.
    DOI:
    10.1016/S1470-2045(21)00065-6
    Trial ID:
    KEYNOTE-054; 2014-004944-37
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.